Barinthus Biotherapeutics plc (BRNS)
NASDAQ: BRNS · Real-Time Price · USD
0.6796
-0.0314 (-4.42%)
May 15, 2026, 4:00 PM EDT - Market closed
Barinthus Biotherapeutics Employees
Barinthus Biotherapeutics had 14 employees as of December 31, 2025. The number of employees decreased by 91 or -86.67% compared to the previous year.
Employees
14
Change (1Y)
-91
Growth (1Y)
-86.67%
Revenue / Employee
n/a
Profits / Employee
-$3,736,500
Market Cap
27.76M
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Dec 31, 2025 | 14 | -91 | -86.67% |
| Dec 31, 2024 | 105 | -25 | -19.23% |
| Dec 31, 2023 | 130 | 23 | 21.50% |
| Dec 31, 2022 | 107 | 35 | 48.61% |
| Dec 31, 2021 | 72 | 24 | 50.00% |
| Mar 31, 2021 | 49 | - | - |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| IGC Pharma | 70 |
| Vistagen Therapeutics | 59 |
| Werewolf Therapeutics | 39 |
| Kyntra Bio | 34 |
| ABVC BioPharma | 19 |
| Sensei Biotherapeutics | 15 |
| Serina Therapeutics | 13 |
| Neuphoria Therapeutics | 8 |
BRNS News
- 17 days ago - Barinthus Bio Reports First Quarter 2026 Financial Results and Updates on Corporate Developments - GlobeNewsWire
- 2 months ago - Barinthus Biotherapeutics reports FY25 EPS ($1.64) vs ($1.55) last year - TheFly
- 5 months ago - Barinthus Biotherapeutics announces update on Phase 1 trial of VTP-1000 - TheFly
- 6 months ago - Barinthus Biotherapeutics price target raised to $4 from $3 at H.C. Wainwright - TheFly
- 6 months ago - Barinthus Biotherapeutics reports Q3 EPS (36c) vs (21c) last year - TheFly
- 7 months ago - ChemDiv Continues R&D Services Support for Clywedog Therapeutics Following Merger with Barinthus Therapeutics - PRNewsWire
- 8 months ago - BARINTHUS BIOTHERAPEUTICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Merger of Barinthus Biotherapeutics plc - BRNS - Business Wire
- 8 months ago - Barinthus Biotherapeutics to Combine with Clywedog Therapeutics to Target Metabolic and Autoimmune Diseases - GlobeNewsWire